PMID- 15258994
OWN - NLM
STAT- MEDLINE
DCOM- 20040920
LR  - 20151119
IS  - 0022-3417 (Print)
IS  - 0022-3417 (Linking)
VI  - 203
IP  - 4
DP  - 2004 Aug
TI  - Change of HER-2/neu status in a subset of distant metastases from breast 
      carcinomas.
PG  - 918-26
AB  - It is assumed that HER-2/neu status remains consistent in breast carcinoma during 
      metastatic spread, but in most previous studies primary tumours were compared 
      with concurrent regional lymph node metastases. The present study investigated 31 
      breast carcinomas and their corresponding lymph node and distant metastases for 
      HER-2/neu status by immunohistochemistry (HercepTest) and fluorescence in situ 
      hybridization (FISH) (PathVysion). In 14 cases, serum HER-2/neu (SHER-2) was 
      measured sequentially using the Bayer Immuno 1 HER-2/neu assay. Comparing 
      HER-2/neu immunohistochemistry of primary tumours and distant metastases case by 
      case, increased HER-2/neu expression was found in the distant metastases in 15 
      cases (48.4%), three (9.7%) of which showed an increase from score 0 to score 3+. 
      In contrast, lymph node metastases showed the same HER-2/neu expression as the 
      primary tumours, confirmed by FISH. Two cases, which showed HER-2/neu score 3+ 
      and HER-2/neu amplification in the primary tumours, revealed increased SHER-2 
      levels above 50 ng/ml at the first measurement. Five of the 14 cases (36%) showed 
      an increase of SHER-2 above 50 ng/ml towards the end of the patients' life. On 
      the basis of these results, there is evidence that in a subset of breast 
      carcinomas, HER-2/neu amplification and overexpression occur de novo in distant 
      metastases at a late disease stage.
CI  - Copyright 2004 Pathological Society of Great Britain and Ireland
FAU - Regitnig, Peter
AU  - Regitnig P
AD  - Department of Pathology, Medical University of Graz, Austria.
FAU - Schippinger, Walter
AU  - Schippinger W
FAU - Lindbauer, Mareike
AU  - Lindbauer M
FAU - Samonigg, Hellmut
AU  - Samonigg H
FAU - Lax, Sigurd F
AU  - Lax SF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pathol
JT  - The Journal of pathology
JID - 0204634
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Neoplasm Proteins)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*metabolism
MH  - Breast Neoplasms/*blood/pathology
MH  - Carcinoma, Ductal, Breast/blood/pathology/secondary
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Neoplasm Proteins/blood
MH  - Receptor, ErbB-2/*blood
EDAT- 2004/07/20 05:00
MHDA- 2004/09/21 05:00
CRDT- 2004/07/20 05:00
PHST- 2004/07/20 05:00 [pubmed]
PHST- 2004/09/21 05:00 [medline]
PHST- 2004/07/20 05:00 [entrez]
AID - 10.1002/path.1592 [doi]
PST - ppublish
SO  - J Pathol. 2004 Aug;203(4):918-26. doi: 10.1002/path.1592.